Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immunotherapy
Pharma
FDA limits Keytruda, Opdivo uses in stomach cancer
The two PD-1 inhibitors' FDA labels in gastric, gastroesophageal junction and esophageal cancers have been reduced to PD-L1-positive tumors only.
Angus Liu
Jun 9, 2025 10:50am
ASCO: AZ looks to bring immunotherapy to early stomach cancer
Jun 1, 2025 8:00am
J&J puts ImmunityBio on defense mode in bladder cancer
Apr 27, 2025 12:35pm
Gilead's Trodelvy-Keytruda proposal hits goal in first-line TNBC
Apr 21, 2025 11:29am
BMS follows Roche, AstraZeneca into first-line liver cancer
Apr 11, 2025 1:53pm
ImmunityBio, SII win FDA nod to help combat BCG shortage
Feb 19, 2025 9:01am
